Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Recs

0
Player Avatar Tyrone85 (29.13) Submitted: 2/19/2009 9:57:09 PM : Outperform Start Price: $21.02 EBS Score: -110.09

after/ 1st q of 2009

Featured Broker Partners


Advertisement